These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3461487)

  • 1. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture.
    Ballet F; Robert J; Bouma ME; Vrignaud P; Infante R
    Pharmacol Res Commun; 1986 Apr; 18(4):343-7. PubMed ID: 3461487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells.
    Le Bot MA; Glaise D; Kernaleguen D; Ratanasavanh D; Carlhant D; Riche C; Guillouzo A
    Pharmacol Res; 1991 Oct; 24(3):243-52. PubMed ID: 1659695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.
    Weenen H; van Maanen JM; de Planque MM; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):919-26. PubMed ID: 6589165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
    Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.
    Vrignaud P; Eghbali H; Hoerni B; Iliadis A; Robert J
    Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1307-13. PubMed ID: 3865777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of cultured hepatocytes derived from goat, sheep and cattle in comparative drug metabolism studies.
    van 't Klooster GA; Woutersen-van Nijnanten FM; Blaauboer BJ; Noordhoek J; van Miert AS
    Xenobiotica; 1994 May; 24(5):417-28. PubMed ID: 8079501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin glucuronidation and UGT2B7 developmental expression.
    Zaya MJ; Hines RN; Stevens JC
    Drug Metab Dispos; 2006 Dec; 34(12):2097-101. PubMed ID: 16985101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytosolic sulfotransferase SULT1C4 mediates the sulfation of doxorubicin and epirubicin.
    Luo L; Zhou C; Hui Y; Kurogi K; Sakakibara Y; Suiko M; Liu MC
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):163-6. PubMed ID: 26948952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of epirubicin and metabolites with repeated courses to cancer patients.
    Morris RG; Kotasek D; Paltridge G
    Eur J Clin Pharmacol; 1991; 40(5):481-7. PubMed ID: 1884722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of doxorubicin handling by isolated hepatocytes is a valuable indicator for restored cell function.
    Crivellato E; Donini A; Baccarani U; Lavaroni S; Candussio L; Degrassi A; Bresadola F
    Histochem J; 2000 Sep; 32(9):535-43. PubMed ID: 11127974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics and metabolism of epirubicin in cancer patients in an advanced stage].
    Strocchi E; Camaggi CM; Pannuti F
    G Ital Chemioter; 1985; 32(1):13-20. PubMed ID: 3868635
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
    Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
    Salvatorelli E; Menna P; Gianni L; Minotti G
    J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of epidoxorubicin in animals: absence of glucuronidation.
    Maessen PA; Mross KB; Pinedo HM; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1987; 20(1):85-7. PubMed ID: 3476219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
    Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.
    Robert J; David M; Granger C
    Cancer Chemother Pharmacol; 1990; 27(2):147-50. PubMed ID: 2249331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
    Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
    J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.